Telix's proposed initial public offering in the United States

Telix Pharmaceuticals Limited (ASX: $TLX) has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission for a proposed initial public offering of its American Depository Shares (ADSs) in the U.S. The Company has applied to list the ADSs on the Nasdaq Global Market under the symbol 'TLX'. The number of ordinary shares to be represented by each ADS, the number of ADSs to be offered, and the price per ADS for the proposed Offering have not yet been determined. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed.

Executive Commentary on Telix's Proposed Initial Public Offering

We are excited to announce the filing of the registration statement for our proposed initial public offering in the United States. This marks a significant step in our efforts to expand our presence and provide access to our American Depository Shares to investors in the U.S. We believe that this Offering will enable us to further advance our clinical and commercial stage products, addressing unmet medical needs in oncology and rare diseases. We look forward to working with Jefferies, Morgan Stanley, Truist Securities, and William Blair as our joint book-running managers for the proposed Offering.

Summary of Telix's Proposed Initial Public Offering

Telix Pharmaceuticals Limited (ASX: $TLX) has taken a major stride by filing a registration statement for a proposed initial public offering of its American Depository Shares in the United States. The Company aims to list the ADSs on the Nasdaq Global Market under the symbol 'TLX'. While the specific details such as the number of ordinary shares per ADS, the number of ADSs to be offered, and the price per ADS are yet to be determined, Telix has expressed its commitment to addressing significant unmet medical needs in oncology and rare diseases through its clinical and commercial stage products. The proposed Offering, subject to market conditions, is a testament to Telix's ambitions to expand its reach and provide access to its innovative portfolio to a broader investor base. Telix's move to file the registration statement reflects its strategic corporate goals and its dedication to advancing radiopharmaceuticals and associated medical devices for the benefit of patients worldwide.